Stereotaxis

Stereotaxis Announces $15 Million Common Stock Financing

Retrieved on: 
Tuesday, May 26, 2020
Computer-assisted surgery, Stereotaxis, Stock market, Stock, Microeconomics

Stereotaxis is issuing approximately 3.66 million shares of registered common stock at a purchase price of $4.10 per share, for gross and net proceeds of approximately $15 million.

Key Points: 
  • Stereotaxis is issuing approximately 3.66 million shares of registered common stock at a purchase price of $4.10 per share, for gross and net proceeds of approximately $15 million.
  • The purchase price reflects a 9% premium to Stereotaxis 10-day volume-weighted average trading price.
  • Additional details regarding the offering will be included in the Form 8-K to be filed by Stereotaxis with the Securities and Exchange Commission.
  • Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures.

Stereotaxis Reports 2020 First Quarter Financial Results

Retrieved on: 
Tuesday, May 5, 2020
Computer-assisted surgery, Stereotaxis

ST. LOUIS, May 05, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the first quarter ended March 31, 2020.

Key Points: 
  • ST. LOUIS, May 05, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the first quarter ended March 31, 2020.
  • Revenue for the first quarter of 2020 totaled $5.8 million compared to $7.0 million in the prior year first quarter.
  • Operating expenses in the quarter of $6.9 million were 11% lower than the prior year first quarter.
  • Negative free cash flow for the first quarter was ($2.2) million, compared to ($1.8) million in the prior year first quarter.

Stereotaxis to Report First Quarter 2020 Financial Results on May 5, 2020

Retrieved on: 
Thursday, April 30, 2020
Computer-assisted surgery, Stereotaxis

To access a replay of the conference call, dial 1-855-859-2056 (US and Canada) or 1-404-537-3406 (International) and give the participant pass code 9794597.

Key Points: 
  • To access a replay of the conference call, dial 1-855-859-2056 (US and Canada) or 1-404-537-3406 (International) and give the participant pass code 9794597.
  • Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures.
  • Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory.
  • The core components of Stereotaxis systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere.

Stereotaxis Reports 2019 Full Year Financial Results

Retrieved on: 
Tuesday, March 10, 2020
Medical devices, Computer-assisted surgery, Stereotaxis, New York Stock Exchange, Cash and cash equivalents, Fischel, Economy of the United States

ST. LOUIS, March 10, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2019.

Key Points: 
  • ST. LOUIS, March 10, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2019.
  • The past year was transformative for Stereotaxis with significant progress financially, commercially and technologically, said David Fischel, Chairman and CEO.
  • Key accomplishments in 2019 include:
    Successful integration with Acutus Medicals advanced mapping technology and implementation of an OpenMappingAPI software architecture.
  • At December 31, 2019, Stereotaxis had cash and cash equivalents of $30.2 million and no debt.

Stereotaxis Earns FDA Clearance and Announces U.S. Launch of Genesis Robotic Magnetic Navigation System

Retrieved on: 
Friday, March 6, 2020
Medicine, Computer-assisted surgery, Stereotaxis, Robotic magnetic navigation, Biotechnology, RMN

Genesis is a leap forward in Robotic Magnetic Navigation technology, said David Fischel, Chairman and CEO.

Key Points: 
  • Genesis is a leap forward in Robotic Magnetic Navigation technology, said David Fischel, Chairman and CEO.
  • Robotic Magnetic Navigation (RMN) introduces the benefits of robotic precision and safety to cardiac ablation, a common minimally invasive procedure to treat arrhythmias.
  • The Genesis RMN System has FDA clearance to navigate an array of compatible interventional devices broadly within all chambers of the heart and coronary vasculature, and throughout the neuro and peripheral vascular system.
  • Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures.

Stereotaxis to Present at Three Investor Conferences in March

Retrieved on: 
Wednesday, February 26, 2020
Articles, Computer-assisted surgery, Medical devices, Technology, Stereotaxis, Educational technology, Fischel

We appreciate the invitations to these conferences and look forward to sharing with the investment community Stereotaxis differentiated technology, clinical value, and growth strategy.

Key Points: 
  • We appreciate the invitations to these conferences and look forward to sharing with the investment community Stereotaxis differentiated technology, clinical value, and growth strategy.
  • One-on-one meetings with Mr. Fischel can be arranged through registration with these conferences.
  • Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures.
  • The core components of Stereotaxis systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere.

Stereotaxis to Report Fourth Quarter and Full Year 2019 Financial Results on March 10, 2020

Retrieved on: 
Wednesday, February 26, 2020
Computer-assisted surgery, Stereotaxis

To access the live call, dial 800-367-2403 (US and Canada) or 334-777-6978 (International) and give the participant pass code 9066267.

Key Points: 
  • To access the live call, dial 800-367-2403 (US and Canada) or 334-777-6978 (International) and give the participant pass code 9066267.
  • Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures.
  • Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory.
  • The core components of Stereotaxis systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere.

Stereotaxis to Ring the Opening Bell® of the New York Stock Exchange

Retrieved on: 
Thursday, January 16, 2020
Computer-assisted surgery, Medical devices, Stereotaxis, Bell ringing, Change ringing, Ringing, Technology

In addition to television coverage of the ceremony, the New York Stock Exchange will live stream the Opening Bell ringing on its website: https://www.nyse.com/bell .

Key Points: 
  • In addition to television coverage of the ceremony, the New York Stock Exchange will live stream the Opening Bell ringing on its website: https://www.nyse.com/bell .
  • A video of the bell-ringing will also be archived on that same page following the livestream.
  • Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures.
  • The core components of Stereotaxis systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere.

First Patients Treated in New Robotic Arrhythmia Care Program at Overland Park Regional Medical Center

Retrieved on: 
Monday, December 16, 2019
Medicine, Medical technology, Medical devices, Computer-assisted surgery, Stereotaxis, Robotic magnetic navigation, Heart arrhythmia

ST. LOUIS, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that HCA Midwest Healththe largest healthcare system in the Kansas City regionhas launched a new robotic arrhythmia care program based at Overland Park Regional Medical Center (OPRMC).

Key Points: 
  • ST. LOUIS, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that HCA Midwest Healththe largest healthcare system in the Kansas City regionhas launched a new robotic arrhythmia care program based at Overland Park Regional Medical Center (OPRMC).
  • Installation of the Stereotaxis Robotic Magnetic Navigation (RMN) System was recently completed, and the first patients have been successfully treated using the technology at Overland Park Regional Medical Center .
  • Stereotaxis partnership with HCA Midwest Health brings new, leading-edge treatment options for patients who have a cardiac arrhythmia.
  • The new cardiac arrhythmia labs at OPRMC were recently opened and are currently treating patients, said Dr. Lakkireddy.

Stereotaxis CEO to Present at the 12th Annual LD Micro Main Event Investor Conference

Retrieved on: 
Wednesday, December 4, 2019
Computer-assisted surgery, Stereotaxis, Medicine, Fischel, New York Stock Exchange, Heart arrhythmia, Robotics

ST. LOUIS, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today its Chairman and Chief Executive Officer, David Fischel, will present at the 12th Annual LD Micro Main Event investor conference.

Key Points: 
  • ST. LOUIS, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today its Chairman and Chief Executive Officer, David Fischel, will present at the 12th Annual LD Micro Main Event investor conference.
  • Mr. Fischel will present an overview of Stereotaxis on Tuesday, December 10, 2019 at 8:00 a.m. PT, discussing the companys technology, clinical value, recent innovations, and commercial growth strategy.
  • This is an exciting time for Stereotaxis, specifically, and for the progress of robotics more broadly in medicine, says Mr. Fischel.
  • We look forward to engaging with participants of the LD Micro Main Event.